Zeno illustrated growth inhibition by cell cycle arrest as well as induction of ADCC against NRG1-altered breast and lung cancer cell lines in preclinical in vitro, SLC3A2-NRG1 and CD74-NRG1 gene fusions lung cancer patient-derived xenograft models (PDXs) showed suppressed growth inhibition and tumor regression. The gene discussed is SLC3A2; the disease is lung carcinoma.